ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Indianapolis, IN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Cancer
Carcinoma
Small Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Triple Negative Breast Cancer

Lung Cancer trials near Indianapolis, IN, USA:

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)

The study treatment will consist of a platinum drug (carboplatin or cisplatin per investigator's choice) plus etoposide plus durvalumab plus monalizu...

Enrolling
Small Cell Lung Cancer
Extensive Stage Small Cell Lung Cancer
Drug: Etoposide
Drug: Carboplatin or Cisplatin

Phase 2

Hirva Mamdani

Indianapolis, Indiana, United States and 3 other locations

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36)

This is a multicenter, randomized, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T Syst ...

Enrolling
Non-small Cell Lung Cancer
Drug: Pembrolizumab (MK-3475) 200 mg
Device: NovoTTF-200T

Phase 2

NovoCure
NovoCure

Indianapolis, Indiana, United States and 23 other locations

Locations recently updated

Testing Experimental Anti-cancer Drug SLC-391 with an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

combination with pembrolizumab in participants with non-small cell lung cancer (NSCLC).Each treatment cycle lasts 21 days. Particip...

Enrolling
Lung Cancer Metastatic
Lung Cancer Stage IV
Biological: pembrolizumab
Drug: SLC-391

Phase 1, Phase 2

SignalChem Lifesciences

Indianapolis, Indiana, United States and 12 other locations

Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

This phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung ...

Enrolling
Stage IVA Lung Cancer AJCC v8
Recurrent Lung Small Cell Carcinoma
Drug: Temozolomide
Biological: Atezolizumab

Phase 2

Dwight Owen

Indianapolis, Indiana, United States and 4 other locations

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS...

Enrolling
Small-Cell Lung Cancer
Extensive-Stage Small-Cell Lung Cancer
Drug: Tarlatamab
Drug: Durvalumab

Phase 3

Amgen
Amgen

Indianapolis, Indiana, United States and 95 other locations

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as...

Active, not recruiting
Small Cell Lung Cancer
Drug: Durvalumab
Other: Placebo

Phase 3

AstraZeneca
AstraZeneca

Muncie, Indiana, United States and 182 other locations

Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

This open-label, non-randomized Phase II trial is designed to assess the safety and tolerability of GT103 in combination with pembrolizumab in adult...

Active, not recruiting
Recurrent Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
Drug: GT103
Drug: Pembrolizumab

Phase 2

Jeffrey Clarke

Indianapolis, Indiana, United States and 5 other locations

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304)

The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).

Active, not recruiting
Small Cell Lung Cancer (SCLC)
Drug: Topotecan
Drug: Amrubicin

Phase 3

Amgen
Amgen

Indianapolis, Indiana, United States and 222 other locations

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

of previously-untreated patients with extensive stage small cell lung cancer. Patients will receive initial chemo-immunotherapy fol...

Enrolling
Extensive Stage Small Cell Lung Cancer
Drug: Cisplatin
Drug: Ceralasertib

Phase 2

Muhammad Furqan

Indianapolis, Indiana, United States and 4 other locations

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non- ...

Enrolling
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Procedure: Magnetic Resonance Imaging
Biological: Ramucirumab

Phase 2

SWOG Cancer Research Network
SWOG Cancer Research Network

Indianapolis, Indiana, United States and 221 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems